Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06209177 | Study of ARO-CFB in Adult Healthy Volunteers | PHASE1 | COMPLETED | 49 | — | — | Apr 5, 2024 | Mar 6, 2026 | May 20, 2026 | 1 | New Zealand |
| Arm | Type | Description |
|---|---|---|
| ARO-CFB (Healthy Volunteers) | EXPERIMENTAL | 1 or 2 doses of ARO-CFB by subcutaneous (sc) injection |
| Placebo (Healthy Volunteers) | EXPERIMENTAL | placebo calculated volume to match active treatment by sc injection |
| Name | Type | Description |
|---|---|---|
| ARO-CFB | DRUG | ARO-CFB for sc injection |
| Placebo | DRUG | sterile normal saline (0.9% NaCl for sc injection) |
Inclusion Criteria: * Willing to provide written informed consent and to comply with study requirements * Female participants must be non-pregnant/non-lactating * Healthy volunteers must be willing to be vaccinated with a meningococcal and pneumococcal vaccine. IgAN participants must have been vacc...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 11 | PHASE3 | BION-1301, LNP023, Atrasentan, Zigakibart, zigakibart |
| Vera Therapeutics, Inc. Class A | VERA | 4 | PHASE3 | Atacicept |
| Travere Therapeutics, Inc. | TVTX | 2 | PHASE3 | sparsentan, irbesartan, Dapagliflozin, Sparsentan |
| Biogen Inc. | BIIB | 1 | PHASE3 | Felzartamab |
| Vertex Pharmaceuticals Incorporated | VRTX | 2 | PHASE3 | Povetacicept |
| AstraZeneca PLC | AZN | 2 | PHASE3 | Ravulizumab |
| Biohaven Ltd. | BHVN | 1 | PHASE1 | BHV-1400 |
| Jade Biosciences, Inc. | JBIO | 1 | PHASE2 | JADE101 |